Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol. 2009 Feb 1;27(4):653.

PMID:
18421054
2.

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.

Whyte S, Pandor A, Stevenson M, Rees A.

Health Technol Assess. 2010 Oct;14(Suppl. 2):47-53. doi: 10.3310/hta14suppl2/07. Review.

3.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
4.

Capecitabine plus oxaliplatin for the treatment of colorectal cancer.

Carrato A, Gallego-Plazas J, Guillén-Ponce C.

Expert Rev Anticancer Ther. 2008 Feb;8(2):161-74. doi: 10.1586/14737140.8.2.161. Review.

PMID:
18279056
5.

Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?

Twelves C.

Oncology (Williston Park). 2002 Dec;16(12 Suppl No 14):23-6. Review.

PMID:
12520636
6.

XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L.

Cancer Invest. 2016;34(2):94-104. doi: 10.3109/07357907.2015.1104689. Epub 2016 Feb 11. Review.

PMID:
26864862
7.
8.

Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.

Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S.

Am J Clin Oncol. 2015 Apr;38(2):227-33. doi: 10.1097/COC.0b013e3182a2d7b8. Review.

PMID:
25806713
9.

Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.

Giantonio BJ.

Semin Oncol. 2006 Oct;33(5 Suppl 10):S15-8. Review.

PMID:
17145520
10.

Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Beatty GL, Giantonio BJ.

Expert Rev Anticancer Ther. 2008 May;8(5):683-8. doi: 10.1586/14737140.8.5.683. Review.

PMID:
18471041
11.

[Recent results of irinotecan therapy in colorectal cancer].

Láng I, Hitre E.

Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17. Review. Hungarian.

12.

[The development of the first line treatment of metastatic colorectal cancer (mCRC)].

Landherr L, Nagykálnai T.

Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1. Review. Hungarian.

13.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
14.

Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?

Douillard JY, Bennouna J, Senellart H.

Clin Colorectal Cancer. 2008 May;7(3):206-11. doi: 10.3816/CCC.2008.n.029. Review.

PMID:
18621641
15.

Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.

Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R.

Med Oncol. 2010 Sep;27(3):585-91. doi: 10.1007/s12032-009-9253-5. Epub 2009 Jun 13. Review.

PMID:
19526201
16.

Anti-angiogenic therapies for metastatic colorectal cancer.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Review.

PMID:
19588372
17.

The future development of bevacizumab in colorectal cancer.

Díaz-Rubio E, Schmoll HJ.

Oncology. 2005;69 Suppl 3:34-45. Epub 2005 Nov 21. Review.

PMID:
16301834
18.

New oxaliplatin-based combinations in the treatment of colorectal cancer.

Cassidy J, Hochster H.

Colorectal Dis. 2003 Nov;5 Suppl 3:1-9. Review.

PMID:
23573555
19.

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Whyte S, Pandor A, Stevenson M.

Pharmacoeconomics. 2012 Dec 1;30(12):1119-32. doi: 10.2165/11597210-000000000-00000. Review.

PMID:
23058097
20.

Common side effects and interactions of colorectal cancer therapeutic agents.

Holt K.

J Pract Nurs. 2011 Spring;61(1):7-20. Review. No abstract available.

PMID:
21751717

Supplemental Content

Support Center